OncoMatch/Clinical Trials/NCT06526793
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Is NCT06526793 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Surovatamig for b-cell non-hodgkin lymphoma.
Treatment: Surovatamig — This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Required: CD19 expression (testing required; no eligibility threshold specified)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any prior therapy
relapsed refractory FL (Module 1) and LBCL (Module 2) after at least 2 prior lines of therapy
Lab requirements
Blood counts
anc ≥ 1000/mm3, platelets ≥ 75,000/mm3, hemoglobin ≥ 9 g/dl. transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening
Kidney function
creatinine clearance (crcl) of ≥ 45 ml/min
Liver function
total bilirubin <1.5x uln, ast/alt ≤ 3xuln or < 5 × uln in the presence of lymphoma involvement of the liver
Cardiac function
left ventricular ejection fraction (lvef) ≥ 45% by echocardiogram or muga
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Phoenix, Arizona
- Research Site · Duarte, California
- Research Site · Jacksonville, Florida
- Research Site · Tampa, Florida
- Research Site · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06526793 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received any prior therapy.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify